Literature DB >> 9207995

[Intraductal papillary mucinous tumors of the pancreas. Clinical and morphological aspects in 30 patients].

L Barbe1, P Ponsot, V Vilgrain, B Terris, J F Fléjou, A Sauvanet, J Belghiti, P Hammel, P Ruszniewski, P Bernades.   

Abstract

AIM: Intraductal papillary-mucinous tumors of the pancreas are rare and characterized by a malignant potential. The aim of this study was to clarify their clinical presentation and the performance of different imaging procedures to determine malignancy and tumor extent.
METHODS: Medical records and radiographs of 30 patients with histologically confirmed intraductal papillary-mucinous tumor of the pancreas were reviewed retrospectively. Imaging procedures were compared with pathological data of resected pancreas to evaluate their performances.
RESULTS: The most frequent symptom was acute pancreatitis (37%). The onset of symptoms preceded the diagnosis by 2.5 years. Diabetes mellitus and diarrhea were respectively detected in 33 and 23% of the cases. The combination of CT scan, endoscopic retrograde cholangiopancreatography and endosonography allowed correct diagnosis of intraductal papillary-mucinous tumor of the pancreas in 100% of the cases. Tumor extent could be accurately determined considering the location of cystic dilatation of the pancreatic ducts, the presence of intraductal material or parietal irregularity. Actuarial 2-year survival rate was 43% in patients with malignant tumors. Radiological factors predicting malignancy were: vascular invasion, common bile duct dilatation, stricture of the main pancreatic duct and the presence of solid component in the tumor.
CONCLUSION: The combination of CT scan, ERCP and endosonography provide accurate diagnosis of intraductal papillary-mucinous tumor of the pancreas as well as assessment of tumor extent and malignancy.

Entities:  

Mesh:

Year:  1997        PMID: 9207995

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  5 in total

1.  Intraductal papillary mucinous tumors (IPMT).

Authors:  J Van de Stadt; J Closset; M Gelin
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

2.  Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer.

Authors:  Jing-Ting Jiang; Chang-Ping Wu; Hai-Feng Deng; Ming-Yang Lu; Jun Wu; Hong-Yu Zhang; Wen-Hui Sun; Mei Ji
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

3.  Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma.

Authors:  F Maire; P Hammel; B Terris; F Paye; J-Y Scoazec; C Cellier; M Barthet; D O'Toole; P Rufat; C Partensky; E Cuillerier; P Lévy; J Belghiti; P Ruszniewski
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

Review 4.  MUC1 and MUC2 in pancreatic neoplasia.

Authors:  E Levi; D S Klimstra; A Andea; O Basturk; N V Adsay
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

5.  Total pancreatectomy in six patients with intraductal papillary mucinous tumour of the pancreas: the treatment of choice.

Authors:  J Bendix Holme; N O Jacobsen; M Rokkjaer; A Kruse
Journal:  HPB (Oxford)       Date:  2001       Impact factor: 3.647

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.